GlassScriptPhysician profile
Salman Akhtar
NPI 1639168966
$2,359.61
in general payments reported to CMS, 2019-2025
20 companies · $813 in 2025
The $813 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $11.89 · 2021: $85.74 · 2022: $357 · 2023: $307 · 2024: $458 · 2025: $813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,365 · Travel and Lodging: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,364.64 |
| Travel and Lodging | $213.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $538.97 | 2025 | Symplicity G3 |
| Abbott Laboratories | $320.01 | 2019-2023 | Aveir, Merlin@Home |
| Novartis Pharmaceuticals Corporation | $224.38 | 2019-2025 | |
| Boston Scientific Corporation | $217.66 | 2019-2025 | Watchman Flx, Varithena Administration Pack |
| Abiomed | $160.10 | 2022-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $145.87 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $139.14 | 2022-2025 | Camzyos, Eliquis |
| Amgen INC. | $134.45 | 2024-2025 | Repatha, Repatha |
| Bard Peripheral Vascular, INC. | $114.49 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $84.33 | 2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $45.62 | 2023-2024 | Lifevest |
| Biotronik INC. | $45.50 | 2024 | |
| Pfizer INC. | $33.61 | 2022 | |
| Cvrx, INC. | $29.96 | 2023 | Barostim Neo System |
| Roche Molecular Systems, INC. | $24.49 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $24.37 | 2025 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $22.54 | 2025 | |
| Sanofi-Aventis U.S. LLC | $21.49 | 2024 | |
| Novo Nordisk INC | $20.74 | 2025 | |
| Janssen Pharmaceuticals, INC | $11.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salman Akhtar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.